AG
XENE icon

Artal Group’s Xenon Pharmaceuticals XENE Stock Holding History

Artal Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-381,554
Closed -$14.9M – 99
2024
Q2 		$14.9M Buy
381,554
+128,167
+51% +$5.12M 0.38% 29
2024
Q1 		$10.9M Buy
+253,387
New +$11.7M 0.28% 42
2018
Q4 		– Sell
-250,000
Closed -$3.3M – 117
2018
Q3 		$3.3M Buy
250,000
+100,000
+67% +$1.16M 0.09% 86
2018
Q2 		$1.38M Hold
150,000
– – 0.03% 97
2018
Q1 		$735K Hold
150,000
– – 0.01% 108
2017
Q4 		$424K Hold
150,000
– – 0.01% 119
2017
Q3 		$443K Hold
150,000
– – 0.01% 111
2017
Q2 		$473K Hold
150,000
– – 0.01% 107
2017
Q1 		$600K Buy
+150,000
New +$1.18M 0.01% 94

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Artal Group's XENE Position: Q3 2024 in Review

Artal Group sold out of Xenon Pharmaceuticals (XENE) in Q3 2024, closing a stake of 381,554 shares — an estimated $14.9M sold.

Artal Group first reported a position in XENE in Q1 2017 and held it in 9 quarters. The position peaked at $14.9M in Q2 2024. 203 funds tracked by Wall St. Rank hold XENE as of Q3 2024.

  • Artal Group reported no remaining Xenon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 381,554 Xenon Pharmaceuticals shares in Q3 2024, an estimated $14.9M.
  • Artal Group first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 9 quarters.
  • Artal Group's Xenon Pharmaceuticals position peaked at $14.9M in Q2 2024.
  • 203 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.